There were 796 press releases posted in the last 24 hours and 153,105 in the last 365 days.

Qualitative & Semi-Quantitative Insight from Key Opinion Leaders on Mirikizumab in Moderate-to-Severe UC, 2018 Study

/EIN News/ -- Dublin, Feb. 22, 2019 (GLOBE NEWSWIRE) -- The "KOL Perspectives: Perception of mirikizumab in moderate-to-severe UC" drug pipelines has been added to ResearchAndMarkets.com's offering.

This KOL Insight briefing focuses on KOLs views of mirikizumab in moderate-to-severe UC.

Questions topics

  • Perception of Phase II mirikizumab induction data in UC
  • Perception of mirikizumab's Phase III study in UC
  • Future expectations of mirikizumab in UC
  • Future expectations for mirikizumab in Crohn's disease

Key Highlights

  • All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while flagging the lack of dose response
  • Endoscopic & histological healing highlighted by most KOLs as suitable secondary endpoints in mirikizumab's ongoing Phase III UC trial
  • KOLs could not differentiate the clinical profile of mirikizumab in UC from other anti-IL-23s, and were divided over its dosing regimen.

Scope

  • The insight briefing is based on Sociable Pharma's analysis of primary research with our ulcerative colitis key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs

  • 5 Europe-based & 5 N. America-based
  • Interviews performed during July 2018

KOL data is analyzed to produce

  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts

Reasons to Buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on mirikizumab in moderate-to-severe UC
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Key Topics Covered:

  1. Executive Summary
  2. Background
  3. Research Panel Composition
  4. Results & Implications
  5. Appendix

Companies Mentioned

  • Lilly
  • Takeda
  • Pfizer
  • Janssen

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/cj9csp/qualitative_and?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Gastrointestinal Drugs 

22157.jpg


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.